Intercept Pharmaceuticals (ICPT) Now Covered by Deutsche Bank

Equities research analysts at Deutsche Bank assumed coverage on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a report released on Monday. The brokerage set a “buy” rating and a $103.00 price target on the biopharmaceutical company’s stock. Deutsche Bank’s price objective would suggest a potential upside of 90.00% from the stock’s current price.

Several other research analysts have also weighed in on the company. Wedbush reaffirmed a “buy” rating and issued a $253.00 target price on shares of Intercept Pharmaceuticals in a research report on Friday, January 5th. Goldman Sachs Group lowered Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a report on Wednesday, February 7th. Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Laidlaw raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a report on Wednesday, November 1st. Finally, Citigroup set a $74.00 price objective on Intercept Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, December 21st. Five equities research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company’s stock. Intercept Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $134.71.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up $0.92 during trading hours on Monday, reaching $54.21. The company had a trading volume of 1,178,800 shares, compared to its average volume of 1,086,975. The firm has a market capitalization of $1,370.00, a price-to-earnings ratio of -3.68 and a beta of -2.13. Intercept Pharmaceuticals has a 52-week low of $51.05 and a 52-week high of $135.59. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15.

Several institutional investors and hedge funds have recently modified their holdings of ICPT. Vanguard Group Inc. increased its stake in shares of Intercept Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after buying an additional 57,149 shares during the period. First Trust Advisors LP boosted its position in shares of Intercept Pharmaceuticals by 101.5% in the 4th quarter. First Trust Advisors LP now owns 605,454 shares of the biopharmaceutical company’s stock worth $35,371,000 after purchasing an additional 304,999 shares during the last quarter. Senvest Management LLC bought a new position in shares of Intercept Pharmaceuticals in the 3rd quarter worth $33,883,000. Emerald Advisers Inc. PA bought a new position in shares of Intercept Pharmaceuticals in the 4th quarter worth $9,497,000. Finally, Peregrine Capital Management LLC bought a new position in shares of Intercept Pharmaceuticals in the 4th quarter worth $7,055,000. 75.48% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/12/intercept-pharmaceuticals-icpt-now-covered-by-deutsche-bank-2.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply